Download PDF
Thromb Haemost 2010; 103(05): 968-975
DOI: 10.1160/TH09-08-0525
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care

Giampiero Mazzaglia
1   Health Search, Italian College of General Practitioners, Florence, Italy
,
Alessandro Filippi
2   Italian College of General Practitioners, Florence, Italy
,
Marianna Alacqua
3   IRCCS Centro Neurolesi ‘Bonino-Pulejo’, Messina, Italy
,
Warren Cowell
4   Bayer HealthCare, Uxbridge, UK
,
Annabelle Shakespeare
4   Bayer HealthCare, Uxbridge, UK
,
Lorenzo G. Mantovani
5   CIRFF – Center of Pharmacoeconomics, Federico II University of Naples, Naples, Italy
,
Cosetta Bianchi
6   Bayer HealthCare, Milan, Italy
,
Claudio Cricelli
2   Italian College of General Practitioners, Florence, Italy
› Author Affiliations
Further Information

Publication History

Received: 03 August 2009

Accepted after major revision: 05 January 2010

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

The aims of this study were to investigate trends in the incidence of diagnosed atrial fibrillation (AF), and to identify factors associated with the prescription of antithrombotics (ATs) and to identify the persistence of patients with oral anticoagulant (OAC) treatment in primary care. Data were obtained from 400 Italian primary care physicians providing information to the Health Search/Thales Database from 2001 to 2004. The age-standardised incidence of AF was: 3.9–3.0 cases, and 3.6–3.0 cases per 1,000 person-years in males and females, respectively. During the study period, 2,016 (37.2%) patients had no prescription, 1,663 (30.7%) were prescribed an antiplatelet (AP) agent, 1,440 (26.6%) were prescribed an OAC and 301 (5.5%) had both prescriptions. The date of diagnosis (p = 0.0001) affected the likelihood of receiving an OAC. AP, but not OAC, use significantly increased with a worsening stroke risk profile using the CHADS2 risk score. Older age increased the probability (p < 0.0001) of receiving an AP, but not an OAC. Approximately 42% and 24% of patients persisted with OAC treatment at one and two years, respectively, the remainder interrupted or discontinued their treatment. Underuse and discontinuation of OAC treatment is common in incident AF patients. Risk stratification only partially influences AT management.

Keywords

Antithrombotics - atrial fibrillation - incidence - oral anticoagulant - risk stratification - therapeutic persistence - treatment
 

  • References

  • 1 Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999; 84: 131R-138R.
    CrossrefPubMedGoogle Scholar
  • 2 Lip GY. et al. Atrial fibrillation--the growing epidemic. Heart 2007; 93: 542-543.
    CrossrefPubMedGoogle Scholar
  • 3 Murphy NF. et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 2007; 93: 606-612.
    CrossrefPubMedGoogle Scholar
  • 4 Benjamin EJ. et al. Impact of atrial fibrillation on the risk of death: the Framing-ham Heart Study. Circulation 1998; 98: 946-952.
    CrossrefPubMedGoogle Scholar
  • 5 Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Heart 2006; 92: 155-161.
    PubMedGoogle Scholar
  • 6 Nieuwlaat R. et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
    CrossrefPubMedGoogle Scholar
  • 7 Marini C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-1119.
    CrossrefPubMedGoogle Scholar
  • 8 Jorgensen HS. et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27: 1765-1769.
    CrossrefPubMedGoogle Scholar
  • 9 Fuster V. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
    CrossrefPubMedGoogle Scholar
  • 10 Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97: 1231-1233.
    CrossrefPubMedGoogle Scholar
  • 11 Go AS. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
    PubMedGoogle Scholar
  • 12 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007; 06: 981-993.
    CrossrefPubMedGoogle Scholar
  • 13 Goldstein LB. et al. Primary prevention of ischemic stroke: A statement for health-care professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32: 280-299.
    CrossrefPubMedGoogle Scholar
  • 14 Wood VA, Hewer RL. The prevention and management of stroke. J Public Health Med 1996; 18: 423-431.
    CrossrefPubMedGoogle Scholar
  • 15 Majeed A. et al. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994–1998: analysis of data from the general practice research database. Heart 2001; 86: 284-288.
    CrossrefPubMedGoogle Scholar
  • 16 Lawrenson R. et al. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299-304.
    CrossrefPubMedGoogle Scholar
  • 17 Cricelli C. et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003; 25: 254-257.
    CrossrefPubMedGoogle Scholar
  • 18 Filippi A. et al. The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J 2005; 06: 311-314.
    PubMedGoogle Scholar
  • 19 Filippi A. et al. Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. Ital Heart J 2005; 06: 49-51.
    PubMedGoogle Scholar
  • 20 Mazzaglia G. et al. Screening of older community-dwelling people at risk for death and hospitalization: the Assistenza Socio-Sanitaria in Italia project. J Am Geriatr Soc 2007; 55: 1955-1960.
    CrossrefPubMedGoogle Scholar
  • 21 Gage BF. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864-2870.
    CrossrefPubMedGoogle Scholar
  • 22 Poli D. et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009; 101: 367-372.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Holbrook AM. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-1106.
    CrossrefPubMedGoogle Scholar
  • 24 Fitzmaurice DA. et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. Br Med J 2007; 335: 383.
    CrossrefPubMedGoogle Scholar
  • 25 Benjamin EJ. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. J Am Med Assoc 1994; 271: 840-844.
    CrossrefPubMedGoogle Scholar
  • 26 Miyasaka Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
    CrossrefPubMedGoogle Scholar
  • 27 Psaty BM. et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-2461.
    CrossrefPubMedGoogle Scholar
  • 28 Stewart S. et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-521.
    CrossrefPubMedGoogle Scholar
  • 29 Heeringa J. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953.
    CrossrefPubMedGoogle Scholar
  • 30 Gage BF. et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110: 2287-2292.
    CrossrefPubMedGoogle Scholar
  • 31 Friberg L. et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006; 27: 1954-1964.
    CrossrefPubMedGoogle Scholar
  • 32 Hylek EM. Contra: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation‘. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 16-17.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Mant JW. Pro: ‘Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation‘. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. Thromb Haemost 2008; 100: 14-15.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Mazzaglia G. et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093-2100.
    CrossrefPubMedGoogle Scholar
  • 35 Filippi A. et al. Detected atrial fibrillation in north Italy: rates, calculated stroke risk and proportion of patients receiving thrombo-prophylaxis. Fam Pract 2000; 17: 337-339.
    CrossrefPubMedGoogle Scholar
  • 36 Nieuwlaat R. et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-1189.
    CrossrefPubMedGoogle Scholar
  • 37 National Collaborating Centre for Chronic Conditions.. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006.
    PubMedGoogle Scholar
  • 38 Lip GY. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. Thromb Haemost 2008; 100: 11-13.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Hohnloser SH. et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156-21561.
    CrossrefPubMedGoogle Scholar
  • 40 Schalekamp T. et al. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008; 100: 1076-1083.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Go AS. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370-2375.
    CrossrefPubMedGoogle Scholar